Business
AXIM® Biotech Enters Services Agreement With CRO to Begin Clinical Studies On Dronabinol and CBD Chewing Gums
AXIM® Biotech Enters Services Agreement With CRO to Begin Clinical Studies On Dronabinol and CBD Chewing Gums.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\nNEW YORK, April 09, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has entered into a Services Agreement with contract research organization (“CRO”) QPS Netherlands BV, a global leader in contract research, to begin separate bio comparison studies with its two leading drug candidates, MedChew® with dronabinol and CanChew® Rx. Both products are chewing gums containing synthetic tetrahydrocannabinol (THC) and cannabidiol (CBD) respectively, and utilize the company’s patented chewing gum delivery mechanism.\n The CRO will conduct a two open label single dose studies (varying chew duration and concentration) followed by a double-blind, randomized, multiple dose study to test the bioavailability of dronabinol in MedChew®. MedChew® formulated with dronabinol is intended for treatment of chemotherapy-induced nausea and vomiting in cancer and AIDS patients. AXIM intends to register the product on the basis of a 505(b)(2) application. An open-label, randomized, 3 period crossover pharmacokinetic study will be conducted by the CRO on AXIM’s CanChew® Rx product. CanChew® Rx is intended to treat symptoms associated with drug-related psychosis. \"Reaching this agreement is a big step in AXIM’s clinical development program as we work diligently on the stages of trials to get our products to those suffering from a range of symptoms,\" said John Huemoeller, Chief Executive Officer of AXIM® Biotech. \"We are proud to work with a well-respected company such as QPS Netherlands that shares our commitment to excellence to bring well-tested and proven drugs to market. They are experts in their respective fields and I am eager to get this study underway and move forward AXIM’s strategic clinical development program.\" Cancer is the second leading cause of death worldwide, with economic impact in the United States alone equating to $80.2 billion in 2015. A large number of cancer patients undergo chemotherapy and search for relief from a range of symptoms that often accompanies the treatment. To learn more about AXIM® Biotechnologies, Inc., visit http://aximbiotech.com/. About AXIM® Biote...